Sanmano B, Hiruma M, Mizoguchi M, Ogawa H
Department of Dermatology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-8421 Tokyo, Japan.
Mycoses. 2003 Sep;46(8):316-21. doi: 10.1046/j.1439-0507.2003.00895.x.
The present study was designed to determine the lowest dose of orally administered itraconazole and the shortest duration of therapy necessary for treatment of tinea corporis and tinea cruris. For all patients, the itraconazole dose was 100 mg twice a day immediately after meals. Twenty-eight patients received itraconazole on days 1 and 8, 12 patients received itraconazole on days 1 and 2, and five patients received itraconazole only on day 1. Clinical and mycological evaluations were performed at baseline and on day 14. Based on the clinical and mycological responses, treatment efficacy was classified as excellent, good, fair, or poor. "Excellent" and "good" responses made up 86% of the first group, 100% of the second group, and 20% of the third group. A comparison of efficacy ratings of the three regimens showed that the patients who received a single 200-mg dose had a significantly inferior outcome compared with the other two groups. We conclude that an abbreviated oral regimen of itraconazole for treatment of tinea corporis and tinea cruris requires a total dose of at least 400 mg to induce a favorable outcome.
本研究旨在确定口服伊曲康唑治疗体癣和股癣所需的最低剂量以及最短疗程。对所有患者而言，伊曲康唑剂量为每日两次，每次100mg，于饭后立即服用。28例患者在第1天和第8天接受伊曲康唑治疗，12例患者在第1天和第2天接受伊曲康唑治疗，5例患者仅在第1天接受伊曲康唑治疗。在基线期和第14天进行临床和真菌学评估。根据临床和真菌学反应将治疗效果分为优、良、中、差。“优”和“良”反应在第一组中占86%，在第二组中占100%，在第三组中占20%。三种治疗方案的疗效评级比较显示，接受单次200mg剂量的患者与其他两组相比结局明显较差。我们得出结论，伊曲康唑治疗体癣和股癣的简化口服方案需要至少400mg的总剂量才能取得良好疗效。
